
Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma
Patrick Moore, MD Assistant Professor Department of Internal Medicine Rush University Chicago, IL Targeted Oncology: How was idecabtagene vicleucel (ide-cel; Abecma) evaluated in patients with relapsed/refractory multiple myeloma? Patrick Moore, MD: In …